Lundbeck leaps into the Tourette’s pipeline
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Lundbeck needs deals, but what can it afford?
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Esketamine floats past adcom vote
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
Upcoming events – Allergan and Lundbeck await depression and mania data
Allergan needs a win with rapastinel, while Lundbeck's chief exec faces her second clinical challenge.
Daybreak clouds over for Lundbeck
A treatment-resistant schizophrenia drug would have been a blockbuster – but Lundbeck’s high risk, high-reward strategy has not paid off.
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Good luck to those who want to shame Celgene
Celgene is getting unwanted attention for the high price of Revlimid, but its pivotal position in multiple myeloma could help the company resist a shame campaign.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.